$YYAI
Connexa Sports Technologies Inc. Stock $yyai

$yyai Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000149315224028975 Filed on July 25, 2024

Income Statement

Concept	2024 Q3	2024
Revenue	$704.9K	$8.398M
YoY Change	-77.41%	-15.37%
Cost Of Revenue	$432.8K	$5.004M
YoY Change	-80.57%	-29.95%
Gross Profit	$272.1K	$3.394M
YoY Change	-69.52%	22.14%
Gross Profit Margin	38.6%	40.41%
Selling, General & Admin	$3.527M	$9.837M
YoY Change	28.39%	-60.13%
% of Gross Profit	1296.23%	289.86%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$3.527M	$9.837M
YoY Change	28.39%	-60.23%
Operating Profit	-$3.255M	-$6.443M
YoY Change	75.51%	-70.66%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$965.6K	-$9.193M
YoY Change	-195.8%	176.98%
Pretax Income		-$15.64M
YoY Change		-38.14%
Income Tax
% Of Pretax Income
Net Earnings	-$4.221M	-$15.64M
YoY Change	398.46%	-78.02%
Net Earnings / Revenue	-598.77%	-186.19%
Basic Earnings Per Share	-$1.91	-$32.44
Diluted Earnings Per Share	-$1.91	-$32.44
COMMON SHARES
Basic Shares Outstanding	2.659M shares	482.0K shares
Diluted Shares Outstanding	2.206M shares	482.0K shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$1.711M	$229.7K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$1.661M	$1.609M
Prepaid Expenses
Receivables	$258.3K	$273.9K
Other Receivables
Total Short-Term Assets	$21.18M	$19.62M
YoY Change	362.22%	293.1%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.001M	$2.001M
YoY Change	0.0%	-5.44%
TOTAL ASSETS
Total Short-Term Assets	$21.18M	$19.62M
Total Long-Term Assets	$2.001M	$2.001M
Total Assets	$23.19M	$21.62M
YoY Change	252.14%	204.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.932M	$4.705M
YoY Change	-18.97%	-14.41%
Accrued Expenses	$4.168M	$3.405M
YoY Change	-19.81%	-30.67%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.75M	$12.02M
YoY Change	-40.99%	-49.41%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.75M	$12.02M
Total Long-Term Liabilities
Total Liabilities	$13.75M	$12.02M
YoY Change	-44.91%	-53.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$171.6M	-$167.4M
YoY Change	12.46%	10.3%
Common Stock	$180.9M	$176.8M
YoY Change	34.9%	32.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.438M	$9.600M
YoY Change
Total Liabilities & Shareholders Equity	$23.19M	$21.62M
YoY Change	252.14%	204.22%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	-$4.221M		-$15.64M
YoY Change	398.46%		-78.02%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$72.65K		-$3.001M
YoY Change	-127.19%		-52.85%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities			-$16.50M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$6.000M	$17.96M
YoY Change			105.4%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.615M		$19.48M
YoY Change	-368.71%		234.62%
NET CHANGE
Cash From Operating Activities	-$72.65K		-$3.001M
Cash From Investing Activities			-$16.50M
Cash From Financing Activities	$1.615M		$19.48M
Net Change In Cash	$1.482M		$27.61K
YoY Change	-521.14%		-105.96%
FREE CASH FLOW
Cash From Operating Activities	-$72.65K		-$3.001M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001674440
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent		usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2023	CNXA	Loss On Conversion Of Accounts Payable To Common Stock LossOnConversionOfAccountsPayableToCommonStock		usd
CY2024	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax		usd
CY2024	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax		usd
CY2024	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2024	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
CY2023	CNXA	Stock Issued During Period Value Cashless Exercise Of Warrants StockIssuedDuringPeriodValueCashlessExerciseOfWarrants		usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2024	CNXA	Stock Issued During Period Cashless Exercise Of Warrants Value StockIssuedDuringPeriodCashlessExerciseOfWarrantsValue		usd
CY2024	CNXA	Stock Issued During Period Value Fractional Adjustment In Reverse Split StockIssuedDuringPeriodValueFractionalAdjustmentInReverseSplit		usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2024	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
CY2024	CNXA	Noncash Transaction Costs NoncashTransactionCosts		usd
CY2023	CNXA	Settlement Expense SettlementExpense		usd
CY2023	CNXA	Loss On Settlement Of Accounts Payable LossOnSettlementOfAccountsPayable		usd
CY2024	CNXA	Increase Decrease In Interest Payable Related Party IncreaseDecreaseInInterestPayableRelatedParty		usd
CY2024	CNXA	Increase Decrease In Interest Payable Related Party IncreaseDecreaseInInterestPayableRelatedParty		usd
CY2024	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations		usd
CY2023	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments		usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations		usd
CY2024	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations		usd
CY2023	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations		usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024	CNXA	Conversion Of Convertible Notes Payable And Accrued Interest To Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestToCommonStock		usd
CY2023	CNXA	Warrants Granted For Deferred Compensation WarrantsGrantedForDeferredCompensation		usd
CY2024	CNXA	Derivative Liability Recorded For Shares And Warrants Issued In Private Placement DerivativeLiabilityRecordedForSharesAndWarrantsIssuedInPrivatePlacement		usd
CY2024	us-gaap	Notes Issued1 NotesIssued1		usd
CY2024	CNXA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercised
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023	CNXA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercised
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2024	CNXA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceForfeited
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2023	CNXA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceForfeited
CY2024	CNXA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpired
CY2023	CNXA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpired
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount		usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount		usd
CY2024	CNXA	Income Tax Reconciliation Stock Options IncomeTaxReconciliationStockOptions		usd
CY2024	CNXA	Income Tax Recociliation Interest Deferral IncomeTaxRecociliationInterestDeferral		usd
CY2024	CNXA	Income Tax Recociliation Accrued Legal IncomeTaxRecociliationAccruedLegal		usd
CY2024	CNXA	Income Tax Recociliation Loss On Extinguishment Of Debt IncomeTaxRecociliationLossOnExtinguishmentOfDebt		usd
CY2024	CNXA	Income Tax Recociliation Accrued Payroll IncomeTaxRecociliationAccruedPayroll		usd
CY2023	CNXA	Income Tax Recociliation Accrued Payroll IncomeTaxRecociliationAccruedPayroll		usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	CNXA	Disposal Group Including Discontinued Operation Other Income Loss DisposalGroupIncludingDiscontinuedOperationOtherIncomeLoss		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-04-30
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	1960570.50	usd
CY2024	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.001
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2659149	shares
CY2024	dei	Auditor Firm AuditorFirmId	5968
CY2024	dei	Auditor Name AuditorName	OLAYINKA OYEBOLA & CO.
CY2024	dei	Auditor Location AuditorLocation	Lagos, Nigeria
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	229705	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	202095	usd
CY2024Q2	us-gaap	Short Term Investments ShortTermInvestments	16500000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	273874	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	399680	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1609196	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	3189766	usd
CY2024Q2	CNXA	Prepaid Inventory Current PrepaidInventoryCurrent	810978	usd
CY2023Q2	CNXA	Prepaid Inventory Current PrepaidInventoryCurrent	936939	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	197871	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	263020	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	19621624	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	4991500	usd
CY2024Q2	us-gaap	Other Receivables OtherReceivables	2000000	usd
CY2023Q2	us-gaap	Other Receivables OtherReceivables	2000000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14791	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	101281	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	2001000	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	2116072	usd
CY2024Q2	us-gaap	Assets Assets	21622624	usd
CY2023Q2	us-gaap	Assets Assets	7107572	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4704596	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5496629	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3405372	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4911839	usd
CY2024Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	5433	usd
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	10489606	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	418455	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	255648	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	22971	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	12022810	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	23767491	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1953842	usd
CY2024Q2	us-gaap	Liabilities Liabilities	12022810	usd
CY2023Q2	us-gaap	Liabilities Liabilities	25721333	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1828541	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1828541	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16929	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16929	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	1828	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	17	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	176801473	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	132994320	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-167387028	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151750610	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	183541	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	142512	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	9599814	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-18613761	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21622624	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7107572	usd
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8398049	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9922799	usd
CY2024	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5004375	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7144335	usd
CY2024	us-gaap	Gross Profit GrossProfit	3393674	usd
CY2023	us-gaap	Gross Profit GrossProfit	2778464	usd
CY2024	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1565006	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1928198	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8271823	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22743877	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65164	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	9836829	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	24737239	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-6443155	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-21958775	usd
CY2024	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1067806	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4095030	usd
CY2024	CNXA	Loss On Conversion Of Accounts Payable To Common Stock LossOnConversionOfAccountsPayableToCommonStock	289980	usd
CY2024	CNXA	Gain Loss On Change In Fair Value Of Derivatives Liability GainLossOnChangeInFairValueOfDerivativesLiability	7635612	usd
CY2023	CNXA	Gain Loss On Change In Fair Value Of Derivatives Liability GainLossOnChangeInFairValueOfDerivativesLiability	10950017	usd
CY2024	CNXA	Derivative Expense DerivativeExpense	14119784	usd
CY2023	CNXA	Derivative Expense DerivativeExpense	8995962	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9193263	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3319050	usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	-4461968	usd
CY2023	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-41413892	usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-45875860	usd
CY2024	CNXA	Income Loss From Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15636418	usd
CY2023	CNXA	Income Loss From Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-71153685	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15636418	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-71153685	usd
CY2024	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	41029	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	87550	usd
CY2024	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-32.44
CY2024	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-32.44
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1806.33
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1806.33
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-3278.25
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-3278.25
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-32.44
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-32.44
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5084.58
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5084.58
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	482005	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	482005	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13994	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13994	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	32511932	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	14046300	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	915545	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	37086	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4195000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	746511	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	87550	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	87550	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-71153685	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-18613761	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-18613761	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-18613761	usd
CY2024	CNXA	Cash Including Warrants CashIncludingWarrants	17961828	usd
CY2024	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	295958	usd
CY2024	CNXA	Stock Issued During Period Value Accounts Payable StockIssuedDuringPeriodValueAccountsPayable	559979	usd
CY2024	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	418454	usd
CY2024	CNXA	Stock Issued During Period Value Satisfaction Of Profit Guarantee On Note Payable StockIssuedDuringPeriodValueSatisfactionOfProfitGuaranteeOnNotePayable	5126286	usd
CY2024	CNXA	Reclassification Of Derivative Liability Upon Amendment Of Agreement ReclassificationOfDerivativeLiabilityUponAmendmentOfAgreement	17258959	usd
CY2024	CNXA	Conversion Of Deferred Copensation To Warrants Equity ConversionOfDeferredCopensationToWarrantsEquity	2187500	usd
CY2024	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	41029	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15636418	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	9599814	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	9599814	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15636418	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-71153685	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	115072	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	11555332	usd
CY2024	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	7635612	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	10950017	usd
CY2024	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	295958	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	37086	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	746511	usd
CY2023	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-41413892	usd
CY2024	CNXA	Derivative Expense DerivativeExpense	14119784	usd
CY2023	CNXA	Derivative Expense DerivativeExpense	8995962	usd
CY2023	CNXA	Noncash Transaction Costs NoncashTransactionCosts	454823	usd
CY2024	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1067806	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4095030	usd
CY2024	CNXA	Settlement Expense SettlementExpense	1928948	usd
CY2024	CNXA	Loss On Settlement Of Accounts Payable LossOnSettlementOfAccountsPayable	289980	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-127448	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1368643	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1580570	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-4413056	usd
CY2024	CNXA	Increase Decrease In Prepaid Inventory IncreaseDecreaseInPrepaidInventory	-125961	usd
CY2023	CNXA	Increase Decrease In Prepaid Inventory IncreaseDecreaseInPrepaidInventory	138308	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-100047	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-430193	usd
CY2024	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1114312	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-598814	usd
CY2024	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1461386	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1072836	usd
CY2024	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	171949	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	158187	usd
CY2023	CNXA	Increase Decrease In Interest Payable Related Party IncreaseDecreaseInInterestPayableRelatedParty	9201	usd
CY2023	CNXA	Increase Decrease In Interest Payable Related Party IncreaseDecreaseInInterestPayableRelatedParty	9201	usd
CY2024	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	12634985	usd
CY2023	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	60326327	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3001433	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10827358	usd
CY2023	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	4461969	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3001433	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6365389	usd
CY2024	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	16500000	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-16500000	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16500000	usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17961828	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8744882	usd
CY2024	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3728000	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2000000	usd
CY2024	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	785509	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	546158	usd
CY2024	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1425326	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4377537	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19478993	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5821187	usd
CY2024	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	50050	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	81295	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	27610	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-462907	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	202095	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	665002	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	229705	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	202095	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	706942	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	482687	usd
CY2023	CNXA	Conversion Of Convertible Notes Payable And Accrued Interest To Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestToCommonStock	14046300	usd
CY2024	CNXA	Shares Issued For Contingent Consideration SharesIssuedForContingentConsideration	418455	usd
CY2023	CNXA	Shares Issued For Contingent Consideration SharesIssuedForContingentConsideration	915545	usd
CY2024	CNXA	Warrants Granted For Deferred Compensation WarrantsGrantedForDeferredCompensation	2187500	usd
CY2023	CNXA	Derivative Liability Recorded For Shares And Warrants Issued In Private Placement DerivativeLiabilityRecordedForSharesAndWarrantsIssuedInPrivatePlacement	4999882	usd
CY2023	us-gaap	Notes Issued1 NotesIssued1	2000000	usd
CY2022Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	3486599	usd
CY2022Q2	us-gaap	Retail Land Sales Receivables Stated Interest Rate RetailLandSalesReceivablesStatedInterestRate	0.75	pure
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-10 reverse stock split
CY2022Q4	us-gaap	Cash Cash	500000	usd
CY2022Q4	us-gaap	Investments Investments	500000	usd
CY2022Q4	CNXA	Gross Revenue Percentage GrossRevenuePercentage	0.07	pure
CY2023Q1	us-gaap	Revenues Revenues	15000000	usd
CY2023Q3	CNXA	Stockholders Equity Description StockholdersEquityDescription	(i) the issuance of (i) 1,274 shares of the our common stock, par value $0.001 per share, that were issued on October 3, 2023, and, (ii) 14,753 shares of our common stock issuable upon exercise of Pre-Funded Warrants at an exercise price of $0.00002 per share, (iii) 16,026 shares of common stock issuable upon the exercise of 5-Year Warrants at an exercise price of $312 per share, (iv) 32,052 shares of common stock issuable upon the exercise of 7.5 Year Warrants at an exercise price of $344 per share and (v) 22,625 shares of our common stock issuable upon the exercise of 5.5 Year Warrants at an at an exercise price per share equal to $1,768per share to Armistice Capital Master Fund Ltd and (ii) a reverse stock split of our common stock within a range of one (1)-for-ten (10) to one (1)-for-forty (40) (“Reverse Stock Split”), with the Board of Directors of the Company to set the specific ratio and determine the date for the reverse split to be effective and any other action deemed necessary to effectuate the Reverse Stock Split, without further approval or authorization of stockholders, at any time within 12 months of the special meeting date.
CY2024Q1	us-gaap	Officers Compensation OfficersCompensation	1000000	usd
CY2024Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1137000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	220265	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	1000000	usd
CY2024Q1	us-gaap	Share Price SharePrice	4.54
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	220265	usd
CY2024Q1	CNXA	Separation Agreement Description SeparationAgreementDescription	the Agreements provide that aggregate payments of (a) $4,500,000 shall be made to the Company in cash by YYEM and (b) $500,000 shall be made to NewCo (as defined under the header “The Separation Agreement”) in cash by YYEM, as follows: (i) $800,000 payable within two (2) business days of the date of the Agreements; (ii) $1,200,000 payable within three (3) business days of the Company changing its ticker symbol from “CNXA” to “YYAI,” or such other symbol as the parties may agree; (iii) $2,000,000 payable at the Closing and (iv) $500,000 to be paid within 30 days from the Closing Date and paid to NewCo. Out of the $4,500,000, the Company paid $2,142,857 to certain companies for arranging the Transactions.
CY2024Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	600000	usd
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-10 to 1-for-100
CY2023Q3	CNXA	Stockholders Equity Description StockholdersEquityDescription	(i) the issuance of (i) 1,274 shares of the our common stock, par value $0.001 per share, that were issued on October 3, 2023, and, (ii) 14,753 shares of our common stock issuable upon exercise of Pre-Funded Warrants at an exercise price of $0.00002 per share, (iii) 16,026 shares of common stock issuable upon the exercise of 5-Year Warrants at an exercise price of $312 per share, (iv) 32,052 shares of common stock issuable upon the exercise of 7.5 Year Warrants at an exercise price of $344 per share and (v) 22,625 shares of our common stock issuable upon the exercise of 5.5 Year Warrants at an at an exercise price per share equal to $1,768per share to Armistice Capital Master Fund Ltd and (ii) a reverse stock split of our common stock within a range of one (1)-for-ten (10) to one (1)-for-forty (40) (“Reverse Stock Split”), with the Board of Directors of the Company to set the specific ratio and determine the date for the reverse split to be effective and any other action deemed necessary to effectuate the Reverse Stock Split, without further approval or authorization of stockholders, at any time within 12 months of the special meeting date.
CY2024Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	3197335.65	usd
CY2024Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3000000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	499584	shares
CY2024Q1	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	6.40
CY2024Q1	us-gaap	Common Stock Convertible Conversion Price Decrease CommonStockConvertibleConversionPriceDecrease	6.40
CY2024Q1	us-gaap	Guaranteed Benefit Liability Net GuaranteedBenefitLiabilityNet	6000000	usd
CY2024Q1	us-gaap	Escrow Deposit EscrowDeposit	2000000	usd
CY2024Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6000000	usd
CY2024Q2	us-gaap	Escrow Deposit EscrowDeposit	2000000	usd
CY2023Q4	CNXA	Voting Shares Issued And Outstanding Percentage Description VotingSharesIssuedAndOutstandingPercentageDescription	On October 12, 2023, the Board of Directors of the Company approved an amendment to the Bylaws of the Company to reduce the percentage of shares of stock, issued and outstanding and entitled to vote, to be present in person or represented by proxy in order to constitute a quorum for the transaction of any business from a majority to thirty-three and one third percent (33 1/3%)
CY2023Q4	CNXA	Consulting Fees ConsultingFees	127500	usd
CY2023Q4	CNXA	Discretionary Compensation DiscretionaryCompensation	127500	usd
CY2024Q1	us-gaap	Investments Investments	16500000	usd
CY2023Q4	CNXA	Bit Price BitPrice	1.00
CY2023Q4	us-gaap	Debt Instrument Convertible Threshold Consecutive Trading Days1 DebtInstrumentConvertibleThresholdConsecutiveTradingDays1	30	integer
CY2024Q1	us-gaap	Shares Issued SharesIssued	10000	shares
CY2024Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	10000	shares
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1000	usd
CY2024Q2	CNXA	Entry Price EntryPrice	700	usd
CY2024Q1	us-gaap	Officers Compensation OfficersCompensation	1000000	usd
CY2024Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1137000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	1000000	usd
CY2024Q1	us-gaap	Share Price SharePrice	4.54
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-167387028	usd
CY2024	us-gaap	Discontinued Operation Equity Method Investment Retained After Disposal Ownership Interest After Disposal DiscontinuedOperationEquityMethodInvestmentRetainedAfterDisposalOwnershipInterestAfterDisposal	0.20	pure
CY2024Q2	us-gaap	Alternative Investment AlternativeInvestment	165000	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zxO1hj4FsEel" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_z0iHYWH9or45">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Accordingly, actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_844_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zyu0InNT1m21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zR6iGzQ12jna">Financial Statement Reclassification</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts within accounts payable, accrued expenses, and certain operating expenses have been reclassified for consistency with the current year presentation and had no effect on the Company’s balance sheet, net loss, shareholders’ deficit or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	40000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	209690	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	995533	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1509985	usd
CY2024Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	770737	usd
CY2023Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1712553	usd
CY2024Q2	CNXA	Capitalized Duty And Freight CapitalizedDutyAndFreight	26171	usd
CY2023Q2	CNXA	Capitalized Duty And Freight CapitalizedDutyAndFreight	517228	usd
CY2024Q2	us-gaap	Inventory Adjustments InventoryAdjustments	183245	usd
CY2023Q2	us-gaap	Inventory Adjustments InventoryAdjustments	550000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1609196	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	3189766	usd
CY2024Q2	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zgei6JG1WsUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zylpZKLZdOm6">Concentration of Credit Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains its cash in bank deposit accounts, the balances of which at times may exceed insured limits. The Company continually monitors its banking relationships and consequently has not experienced any losses in such accounts. While we may be exposed to credit risk, we consider the risk remote and do not expect that any such risk would result in a significant effect on our results of operations or financial condition. See Note 4 for further details on the Company’s concentration of credit risk as well as other risks and uncertainties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	5433	usd
CY2024	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	7635612	usd
CY2023Q2	us-gaap	Derivative Instruments And Hedges Liabilities DerivativeInstrumentsAndHedgesLiabilities	10489606	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	10950017	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4895582	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	153677	usd
CY2024Q2	CNXA	Impairment Of Intangible Asset Finitelived ImpairmentOfIntangibleAssetFinitelived	4740905	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4895582	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	153677	usd
CY2023Q2	CNXA	Impairment Of Intangible Asset Finitelived ImpairmentOfIntangibleAssetFinitelived	4640624	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	101281	usd
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	101281	usd
CY2024Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1304363	usd
CY2023Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1535186	usd
CY2024Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1022751	usd
CY2023Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1720606	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	37212	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	490424	usd
CY2024Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	1041046	usd
CY2023Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	1165623	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3405372	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4911839	usd
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	109737	shares
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	13200000	shares
CY2022Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	846301	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	122222	usd
CY2022Q1	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1	4000000	usd
CY2022Q1	CNXA	Number Of Consigned Goods NumberOfConsignedGoods	13000	integer
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1828541	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1828541	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16929	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16929	shares
CY2024	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1811612	shares
CY2023Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	9486	shares
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10	usd
CY2023Q3	CNXA	Stock Issued During Period Shares Issued Settlement Of Accounts Payable StockIssuedDuringPeriodSharesIssuedSettlementOfAccountsPayable	3375	shares
CY2023Q3	CNXA	Stock Issued During Period Shares Issued Settlement StockIssuedDuringPeriodSharesIssuedSettlement	168	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1350	shares
CY2023Q3	CNXA	Stock Issued During Period Shares Issued Profit Guarantee On Note StockIssuedDuringPeriodSharesIssuedProfitGuaranteeOnNote	4819	shares
CY2023Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	192226	shares
CY2023Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	686	shares
CY2023Q4	CNXA	Stock Issued During Period Shares Issued For Contingent Consideration StockIssuedDuringPeriodSharesIssuedForContingentConsideration	99	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	185408	shares
CY2023Q4	CNXA	Stock Issued During Period Shares Issued Profit Guarantee On Note StockIssuedDuringPeriodSharesIssuedProfitGuaranteeOnNote	4250	shares
CY2023Q4	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	1785	shares
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1 for 40 reverse split
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	71	shares
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	11686	shares
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	5485	shares
CY2022Q4	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	2405	shares
CY2022Q4	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	34	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	350	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	8	shares
CY2024Q2	us-gaap	Shares Issued SharesIssued	2	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	89615	shares
CY2023Q2	CNXA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding	684.20
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	4853	shares
CY2022Q2	CNXA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding	8890.00
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5254438	shares
CY2024	CNXA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceGranted	0.59
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	85706	shares
CY2023	CNXA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceGranted	234.00
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	472651	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	179	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	944	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	4871223	shares
CY2024Q2	CNXA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding	1.44
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	89615	shares
CY2023Q2	CNXA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding	684.20
CY2024Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	3712223	usd
CY2023Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2344529	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P9Y3M
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P6Y5M12D
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	4871223	shares
CY2024	us-gaap	Payments For Rent PaymentsForRent	9426	usd
CY2023	us-gaap	Payments For Rent PaymentsForRent	4900	usd
CY2022Q1	CNXA	Fair Value Of Common Stock FairValueOfCommonStock	1334000	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	14960	shares
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	418455	usd
CY2024Q1	us-gaap	Cash Cash	16500000	usd
CY2024Q1	us-gaap	Stockholders Equity Period Increase Decrease StockholdersEquityPeriodIncreaseDecrease	4045326	usd
CY2024Q1	us-gaap	Investments Investments	16500000	usd
CY2023Q4	CNXA	Bid Price Per Share BidPricePerShare	1.00
CY2023Q4	us-gaap	Debt Instrument Convertible Threshold Consecutive Trading Days1 DebtInstrumentConvertibleThresholdConsecutiveTradingDays1	30	integer
CY2024Q2	CNXA	Minimum Stockholders Equity Requirement Amount MinimumStockholdersEquityRequirementAmount	5000000	usd
CY2024Q1	CNXA	Separation Agreement Description SeparationAgreementDescription	the Agreements provide that aggregate payments of (a) $4,500,000 shall be made to the Company in cash by YYEM and (b) $500,000 shall be made to NewCo (as defined under the header “The Separation Agreement”) in cash by YYEM, as follows: (i) $800,000 payable within two (2) business days of the date of the Agreements; (ii) $1,200,000 payable within three (3) business days of the Company changing its ticker symbol from “CNXA” to “YYAI,” or such other symbol as the parties may agree; (iii) $2,000,000 payable at the Closing and (iv) $500,000 to be paid within 30 days from the Closing Date and paid to NewCo. Out of the $4,500,000, the Company paid $2,142,857 to certain companies for arranging the Transactions.
CY2024Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	600000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6298000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3049000	usd
CY2024Q2	CNXA	Deferred Tax Assets Stock Options DeferredTaxAssetsStockOptions	7606000	usd
CY2023Q2	CNXA	Deferred Tax Assets Stock Options DeferredTaxAssetsStockOptions	8454000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	186000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	11039000	usd
CY2024Q2	CNXA	Deferred Tax Assets Related Party Accruals DeferredTaxAssetsRelatedPartyAccruals	1013000	usd
CY2023Q2	CNXA	Deferred Tax Assets Related Party Accruals DeferredTaxAssetsRelatedPartyAccruals	1001000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	63000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	133000	usd
CY2024Q2	CNXA	Deferred Tax Assets Interest Deferral DeferredTaxAssetsInterestDeferral	223000	usd
CY2023Q2	CNXA	Deferred Tax Assets Interest Deferral DeferredTaxAssetsInterestDeferral	221000	usd
CY2024Q2	CNXA	Deferred Tax Assets Startup Costs DeferredTaxAssetsStartupCosts	66000	usd
CY2023Q2	CNXA	Deferred Tax Assets Startup Costs DeferredTaxAssetsStartupCosts	81000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	138000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	131000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15593000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24109000	usd
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	2808000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10983000	usd
CY2024	CNXA	Income Tax Reconciliation Debt Discount Amortization IncomeTaxReconciliationDebtDiscountAmortization	3250000	usd
CY2023	CNXA	Income Tax Reconciliation Debt Discount Amortization IncomeTaxReconciliationDebtDiscountAmortization	860000	usd
CY2024	CNXA	Income Tax Reconciliation Related Party Accruals IncomeTaxReconciliationRelatedPartyAccruals	-94000	usd
CY2023	CNXA	Income Tax Reconciliation Related Party Accruals IncomeTaxReconciliationRelatedPartyAccruals	226000	usd
CY2023	CNXA	Income Tax Reconciliation Stock Options IncomeTaxReconciliationStockOptions	-145000	usd
CY2024	CNXA	Income Tax Recociliation Interest Expense IncomeTaxRecociliationInterestExpense	132000	usd
CY2023	CNXA	Income Tax Recociliation Interest Expense IncomeTaxRecociliationInterestExpense	79000	usd
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense Depreciation IncomeTaxReconciliationNondeductibleExpenseDepreciation	20000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Depreciation IncomeTaxReconciliationNondeductibleExpenseDepreciation	-18000	usd
CY2024	CNXA	Income Tax Recociliation Inventory Reserve IncomeTaxRecociliationInventoryReserve	-107000	usd
CY2023	CNXA	Income Tax Recociliation Inventory Reserve IncomeTaxRecociliationInventoryReserve	26000	usd
CY2023	CNXA	Income Tax Recociliation Interest Deferral IncomeTaxRecociliationInterestDeferral	-5000	usd
CY2024	CNXA	Income Tax Recociliation Acquisition Costs IncomeTaxRecociliationAcquisitionCosts	24000	usd
CY2023	CNXA	Income Tax Recociliation Acquisition Costs IncomeTaxRecociliationAcquisitionCosts	260000	usd
CY2023	CNXA	Income Tax Recociliation Accrued Legal IncomeTaxRecociliationAccruedLegal	-76000	usd
CY2023	CNXA	Income Tax Recociliation Loss On Extinguishment Of Debt IncomeTaxRecociliationLossOnExtinguishmentOfDebt	8713000	usd
CY2024	CNXA	Income Tax Recociliation Gain On Change In Fair Value Of Derivatives IncomeTaxRecociliationGainOnChangeInFairValueOfDerivatives	-1603000	usd
CY2023	CNXA	Income Tax Recociliation Gain On Change In Fair Value Of Derivatives IncomeTaxRecociliationGainOnChangeInFairValueOfDerivatives	481000	usd
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-274000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	40000	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1460000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	542000	usd
CY2024Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	6298000	usd
CY2023Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3049000	usd
CY2022Q4	us-gaap	Cash Cash	500000	usd
CY2022Q4	us-gaap	Investments Investments	500000	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	3954149	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	8416117	usd
CY2023	CNXA	Disposal Group Including Discontinued Operation Net Income Loss DisposalGroupIncludingDiscontinuedOperationNetIncomeLoss	-4461968	usd

Files In Submission

Name	View Source	Status
0001493152-24-028975-index-headers.html	Edgar Link	pending
0001493152-24-028975-index.html	Edgar Link	pending
0001493152-24-028975.txt	Edgar Link	pending
0001493152-24-028975-xbrl.zip	Edgar Link	pending
cnxa-20240430.xsd	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
form10-k_006.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
cnxa-20240430_pre.xml	Edgar Link	unprocessable
cnxa-20240430_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cnxa-20240430_cal.xml	Edgar Link	unprocessable
cnxa-20240430_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$YYAI
Connexa Sports Technologies Inc. Stock $yyai

2024 Q3 Form 10-K Financial Statement

#000149315224028975 Filed on July 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YYAI Connexa Sports Technologies Inc. Stock $yyai

2024 Q3 Form 10-K Financial Statement

#000149315224028975 Filed on July 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YYAI
Connexa Sports Technologies Inc. Stock $yyai